Inhibition of basic leucine zipper transcription is a major mediator of atrial dilatation

Cardiovascular Research

Volumn 70, Issue 3, 2006, Pages 543-554

  Kehat, Izhak ^a,b   Heinrich, Ronit ^b   Ben Izhak, Ofer ^a   Miyazaki, Hiroshi ^c   Gutkind, J Silvio ^d   Aronheim, Ami ^b  

^a RAMBAM MEDICAL CENTER   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^c Philips Institute of Oral and Craniofacial Molecular Biology   (United States)

^d NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

Author keywords

Connexins; Gene expression; Hypertrophy; Trial function

Indexed keywords

C JUN DIMERIZATION PROTEIN 2; CONNEXIN 40; LEUCINE ZIPPER PROTEIN; LUCIFERASE; MYOSIN; PROTEIN; TETRACYCLINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISSECTION; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; GENE EXPRESSION REGULATION; GENE TARGETING; GENETIC TRANSCRIPTION; HEART; HEART ATRIUM ENLARGEMENT; HEART ATRIUM FIBRILLATION; LIGHT CHAIN; MOUSE; MOUSE STRAIN; NONHUMAN; NORTHERN BLOTTING; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPORTER GENE; TRANSGENE; WESTERN BLOTTING;

ACTIVATING TRANSCRIPTION FACTOR 3; ANIMALS; BLOTTING, NORTHERN; BLOTTING, WESTERN; CARDIOMEGALY; DEATH, SUDDEN, CARDIAC; DNA; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; ELECTROPHORETIC MOBILITY SHIFT ASSAY; GENE EXPRESSION REGULATION; LEUCINE ZIPPERS; MICE; MICE, TRANSGENIC; MYOCARDIUM; REPRESSOR PROTEINS; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC;

EID: 33646533285     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cardiores.2006.02.018     Document Type: Article

References (39)

1. Braunwald E. Shattuck lecture - Cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. N Engl J Med 337 (1997) 1360-1369
2. Wattigney W.A., Mensah G.A., and Croft J.B. Increasing trends in hospitalization for atrial fibrillation in the United States, 1985 through 1999: implications for primary prevention. Circulation 108 (2003) 711-716
3. Kannel W.B., Wolf P.A., Benjamin E.J., and Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 82 (1998) 2N-9N
4. Psaty B.M., Manolio T.A., Kuller L.H., Kronmal R.A., Cushman M., Fried L.P., et al. Incidence of and risk factors for atrial fibrillation in older adults. Circulation 96 (1997) 2455-2461
5. Liang Q., and Molkentin J.D. Redefining the roles of p38 and JNK signaling in cardiac hypertrophy: dichotomy between cultured myocytes and animal models. J Mol Cell Cardiol 35 (2003) 1385-1394
6. Montclare J.K., Sloan L.S., and Schepartz A. Electrostatic control of half-site spacing preferences by the cyclic AMP response element-binding protein CREB. Nucleic Acids Res 29 (2001) 3311-3319
7. Shaulian E., and Karin M. AP-1 in cell proliferation and survival. Oncogene 20 (2001) 2390-2400
8. Hsu J.C., Bravo R., and Taub R. Interactions among LRF-1, JunB, c-Jun, and c-Fos define a regulatory program in the G1 phase of liver regeneration. Mol Cell Biol 12 (1992) 4654-4665
9. Hai T., and Hartman M.G. The molecular biology and nomenclature of the activating transcription factor/cAMP responsive element binding family of transcription factors: activating transcription factor proteins and homeostasis. Gene 273 (2001) 1-11
10. Mayr B., and Montminy M. Transcriptional regulation by the phosphorylation-dependent factor CREB. Nat Rev Mol Cell Biol 2 (2001) 599-609
11. Rudolph D., Tafuri A., Gass P., Hammerling G.J., Arnold B., and Schutz G. Impaired fetal T cell development and perinatal lethality in mice lacking the cAMP response element binding protein. Proc Natl Acad Sci U S A 95 (1998) 4481-4486
12. Eferl R., Ricci R., Kenner L., Zenz R., Davisd J.-P., Rath M., et al. Liver tumor development: c-Jun antagonizes the proapoptotic activity of p53. Cell 112 (2003) 181-192
13. Hummler E., Cole T.J., Blendy J.A., Ganss R., Aguzzi A., Schmid W., et al. Targeted mutation of the CREB gene: compensation within the CREB/ATF family of transcription factors. Proc Natl Acad Sci U S A 91 (1994) 5647-5651
14. Fentzke R.C., Korcarz C.E., Lang R.M., Lin H., and Leiden J.M. Dilated cardiomyopathy in transgenic mice expressing a dominant-negative CREB transcription factor in the heart. J Clin Invest 101 (1998) 2415-2426
15. Muller F.U., Lewin G., Baba H.A., Boknik P., Fabritz L., Kirchhefer U., et al. Heart-directed expression of a human cardiac isoform of cAMP-response element modulator in transgenic mice. J Biol Chem 280 (2005) 6906-6914
16. Okamoto Y., Chaves A., Chen J., Kelley R., Jones K., Weed H.G., et al. Transgenic mice with cardiac-specific expression of activating transcription factor 3, a stress-inducible gene, have conduction abnormalities and contractile dysfunction. Am J Pathol 159 (2001) 639-650
17. Hsu J.C., Laz T., Mohn K.L., and Taub R. Identification of LRF-1 a leucine zipper protein that is rapidly and highly induced in regenerating liver. Proc Natl Acad Sci U S A 88 (1991) 3511-3515
18. Subramaniam A., Jones W.K., Gulick J., Wert S., Neumann J., and Robbins J. Tissue-specific regulation of the alpha-myosin heavy chain gene promoter in transgenic mice. J Biol Chem 266 (1991) 24613-24620
19. Jin C., Ugai H., Song J., Murata T., Nili F., Sun K., et al. Identification of mouse Jun dimerization protein 2 as a novel repressor of ATF-2. FEBS Lett 489 (2001) 34-41
20. Aronheim A., Zandi E., Hennemann H., Elledge S., and Karin M. Isolation of an AP-1 repressor by a novel method for detecting protein-protein interactions. Mol Cell Biol 17 (1997) 3094-3102
21. Hai T.W., Liu F., Coukos W.J., and Green M.R. Transcription factor ATF cDNA clones: an extensive family of leucine zipper proteins able to selectively form DNA-binding heterodimers. Genes Dev 3 (1989) 2083-2090
22. Liang G., Wolfgang C.D., Chen B.P., Chen T.H., and Hai T. ATF3 gene. Genomic organization, promoter, and regulation. J Biol Chem 271 (1996) 1695-1701
23. Dor Y., Djonov V., Abramovitch R., Itin A., Carmeliet P., et al. Conditional switching of VEGF provides new insights into adult neovascularization and pro-angiogenic therapy. EMBO J 21 (2002) 1939-1947
24. Heinrich R., Livne E., Ben-Izhak O., and Aronheim A. The c-Jun dimerization protein 2 inhibits cell transformation and acts as a tumor suppressor gene. J Biol Chem 279 (2004) 5708-5715
25. Huang C., Sheikh F., Hollander M., Cai C., Becker D., Chu P.H., et al. Embryonic atrial function is essential for mouse embryogenesis, cardiac morphogenesis and angiogenesis. Development 130 (2003) 6111-6119
26. Kistner A., Gossen M., Zimmermann F., Jerecic J., Ullmer C., Lubbert H., et al. Doxycycline-mediated quantitative and tissue-specific control of gene expression in transgenic mice. Proc Natl Acad Sci U S A 93 (1996) 10933-10938
27. van Veen A.A., van Rijen H.V., and Opthof T. Cardiac gap junction channels: modulation of expression and channel properties. Cardiovasc Res 51 (2001) 217-229
28. Seul K.H., Tadros P.N., and Beyer E.C. Mouse connexin40: gene structure and promoter analysis. Genomics 46 (1997) 120-126
29. Yu Z., Redfern C.S., and Fishman G.I. Conditional transgene expression in the heart. Circ Res 79 (1996) 691-697
30. Simon A.M., Goodenough D.A., and Paul D.L. Mice lacking connexin40 have cardiac conduction abnormalities characteristic of atrioventricular block and bundle branch block. Curr Biol 8 (1998) 295-298
31. Bevilacqua L.M., Simon A.M., Maguire C.T., Gehrmann J., Wakimoto H., Paul D.L., et al. A targeted disruption in connexin40 leads to distinct atrioventricular conduction defects. J Interv Card Electrophysiol 4 (2000) 459-467
32. VanderBrink B.A., Sellitto C., Saba S., Link M.S., Zhu W., Homoud M.K., et al. Connexin40-deficient mice exhibit atrioventricular nodal and infra-Hisian conduction abnormalities. J Cardiovasc Electrophysiol 11 (2000) 1270-1276
33. Gaborit N., Steenman M., Lamirault G., Le Meur N., Le Bouter S., Lande G., et al. Human atrial ion channel and transporter subunit gene-expression remodeling associated with valvular heart disease and atrial fibrillation. Circulation 112 (2005) 471-481
34. Neuberger H.R., Schotten U., Verheule S., Eijsbouts S., Blaauw Y., van Hunnik A., et al. Development of a substrate of atrial fibrillation during chronic atrioventricular block in the goat. Circulation 111 (2005) 30-37
35. Sanbe A., Fewell J.G., Gulick J., Osinska H., Lorenz J., Hall D.G., et al. Abnormal cardiac structure and function in mice expressing nonphosphorylatable cardiac regulatory myosin light chain 2. J Biol Chem 274 (1999) 21085-21094
36. Grimm M., Haas P., Willipinski-Stapelfeldt B., Zimmermann W.H., Rau T., Pantel K., et al. Key role of myosin light chain (MLC) kinase-mediated MLC2a phosphorylation in the alpha 1-adrenergic positive inotropic effect in human atrium. Cardiovasc Res 65 (2005) 211-220
37. Xiao H.D., Fuchs S., Campbell D.J., Lewis W., Dudley Jr. S.C., Kasi V.S., et al. Mice with cardiac-restricted angiotensin-converting enzyme (ACE) have atrial enlargement, cardiac arrhythmia, and sudden death. Am J Pathol 165 (2004) 1019-1032
38. Donoghue M., Wakimoto H., Maguire C.T., Acton S., Hales P., Stagliano N., et al. Heart block, ventricular tachycardia, and sudden death in ACE2 transgenic mice with downregulated connexins. J Mol Cell Cardiol 35 (2003) 1043-1053
39. Ciaroni S., Cuenoud L., and Bloch A. Clinical study to investigate the predictive parameters for the onset of atrial fibrillation in patients with essential hypertension. Am Heart J 139 (2000) 814-819